In the context of the coronavirus disease 2019 (COVID-19) pandemic, the global healthcare
community has raced to find effective therapeutic agents against severe acute respiratory …

Abstract The World Health Organization (WHO) declared COVID-19 (novel coronavirus) as a
global pandemic in the middle of March 2020, after the disease spread to more than 150 …

Background and objectives Corticosteroids are commonly used in the treatment of
hospitalized patients with COVID-19. The goals of the present study were to compare the …

ABSTRACT Background Coronavirus disease 2019 (COVID-19) is associated with diffuse
lung damage. Corticosteroids may modulate immune-mediated lung injury and reducing …

The current outbreak of novel COVID-19 challenges the development of an efficient
treatment plan as soon as possible. Several promising treatment options stand out as …

Abstract Background Coronavirus disease 2019 (Covid-19) is associated with diffuse lung
damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby …

Aims To examine the association between dexamethasone use and mortality among
patients hospitalized for COVID‐19. Methods We examined the association between …

Background There are no specific generally accepted therapies for the coronavirus disease
2019 (COVID-19). The full spectrum of COVID-19 ranges from asymptomatic disease to mild …

A clinical interpretation of the Randomized Evaluation of COVID-19 Therapy (RECOVERY)
study was performed to provide a useful tool to understand whether, when, and to whom …

Background Dexamethasone 6 mg daily for 10 days is the recommended treatment for
patients with severe or critical coronavirus disease 2019 (COVID-19). The evidence on the …